• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Medical Officer Conner Edward R. exercised 4,790 shares at a strike of $4.20 and sold $71,850 worth of shares (4,790 units at $15.00) (SEC Form 4)

    9/20/24 5:36:08 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THRD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Conner Edward R.

    (Last) (First) (Middle)
    C/O THIRD HARMONIC BIO, INC.
    1700 MONTGOMERY STREET, SUITE 210

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Third Harmonic Bio, Inc. [ THRD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/19/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/19/2024 M 4,790 A $4.2 4,790 D
    Common Stock 09/19/2024 S(1) 4,790 D $15 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Option Grant (right to buy) $4.2 09/19/2024 M 4,790 (2) 07/27/2032 Common Stock 4,790 $0 373,708 D
    Explanation of Responses:
    1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated May 15, 2023.
    2. 25% of the total shares vest on June 6, 2023, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
    /s/ Christopher Murphy, Attorney-in-Fact 09/20/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $THRD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $THRD

    DatePrice TargetRatingAnalyst
    3/28/2025$23.00 → $5.00Buy → Hold
    Stifel
    2/12/2025$20.00 → $5.00Overweight → Equal-Weight
    Morgan Stanley
    2/11/2025Outperform → Mkt Perform
    Raymond James
    8/9/2024$12.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    6/18/2024$23.00Buy
    Stifel
    6/7/2024$18.00Outperform
    Raymond James
    More analyst ratings

    $THRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Third Harmonic Bio Inc.

      SC 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

      11/14/24 5:46:12 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Third Harmonic Bio Inc.

      SC 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)

      11/14/24 1:28:35 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Third Harmonic Bio Inc.

      SC 13D/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

      11/12/24 6:04:36 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial & Bus. Officer Murphy Christopher M.

      4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

      3/5/25 4:01:29 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial & Bus. Officer Murphy Christopher M.

      4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

      1/17/25 6:10:34 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Dittman Jennifer

      4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

      1/17/25 6:09:33 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    Financials

    Live finance-specific insights

    See more
    • Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

      THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today

      2/11/25 7:00:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Third Harmonic Bio Announces Plan of Liquidation and Dissolution

      Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 Initial distribution expected in the range between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock, expected in the third quarter of 2025 Sale of the Company's assets, including THB335, to be initiated pending stockholder approval of the Plan of Liquidation and Dissolution SAN FRANCISCO, April 14, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD) today announced that the Company's board of directors, after considering opportunities to

      4/14/25 6:45:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

      Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across all assets in the company Strong financial position with cash and cash equivalents totaling $285.1 million as of December 31, 2024 SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024. THB335 Phase 1 Clinical Results In February 2025, the Company reported resu

      3/27/25 8:10:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

      THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today

      2/11/25 7:00:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    Leadership Updates

    Live Leadership Updates

    See more
    • Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

      SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. "Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "Beyond his expertise, Geoff is an excellent cultural fit with our organ

      3/28/24 8:30:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update

      Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion; Pre-IND interaction with the U.S. FDA now complete Program remains on track to file a U.S. IND and initiate a Phase 1 study of THB335 during the first half of 2024 SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Christopher Murphy as Chief Financial and Business Officer. Chris brings extensive experience in business de

      1/4/24 8:00:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Third Harmonic Bio Inc.

      SCHEDULE 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)

      5/15/25 4:37:50 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Third Harmonic Bio Inc.

      SCHEDULE 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

      5/15/25 2:28:43 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Third Harmonic Bio Inc.

      SCHEDULE 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

      5/12/25 10:43:30 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Third Harmonic Bio downgraded by Stifel with a new price target

      Stifel downgraded Third Harmonic Bio from Buy to Hold and set a new price target of $5.00 from $23.00 previously

      3/28/25 8:16:37 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Third Harmonic Bio downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Third Harmonic Bio from Overweight to Equal-Weight and set a new price target of $5.00 from $20.00 previously

      2/12/25 7:12:21 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Third Harmonic Bio downgraded by Raymond James

      Raymond James downgraded Third Harmonic Bio from Outperform to Mkt Perform

      2/11/25 11:05:35 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care